Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Di Nardo D, Fankhauser C, Fischer S, Gravina C, Gremmels H, Heidenreich A, Janisch F, Leão R, Nicolai N, Oing C, Oldenburg J, Shepherd R, Tandstad T, Nicol D. European Association of Urology Guidelines on Testicular Cancer: 2023 Update. Eur Urol. 2023;84(3):289–301. Sep.

Article  PubMed  Google Scholar 

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594–603.

Marandino L, Vogl UM. Mediastinal germ cell tumours: where we are and where we are going—a narrative review. Medistainum. 2022;6:7.

Article  Google Scholar 

Pini GM, Colechia M. Mediastinal germ cell tumors: a narrative review of their traits and aggressiveness features. Mediastinim. 2022;6:5.

Article  Google Scholar 

El-Zaatari ZM, Ro JY. Mediastinal Germ Cell Tumors: A Review and Update on Pathologic, Clinical, and Molecular Features. Adv Anat Pathol. 2021;1;28(5):335–50. Sep.

Article  Google Scholar 

Sharma P, Jha V, Kumar N, Kumar R, Mandal A. Clinicopathological Analysis of Mediastinal Masses: A Mixed Bag of Non-Neoplastic and Neoplastic Etiologies. Turk Patoloji Derg. 2017;33(1):37–46.

PubMed  Google Scholar 

Fichtner A, Richter A, Filmar S, Kircher S, Rosenwald A, Küffer S, Nettersheim D, Oing C, Marx A, Ströbel P, Bremmer F. Primary mediastinal germ cell tumours: an immunohistochemical and molecular diagnostic approach. Histopathology. 2022;80(2):381–96. Jan.

Article  PubMed  Google Scholar 

Bonouvrie K, van der Werff Ten Bosch J, van den Akker M. Klinefelter syndrome and germ cell tumors: review of the literature. Int J Pediatr Endocrinol. 2020;2020:18.

Article  PubMed  PubMed Central  Google Scholar 

Daugaard G, Rørth M, von der Maase H. Skakkebaek NE. Management of extragonadal germ-cell tumors and the significance of bilateral testicular biopsies. Ann Oncol. 1992;3(4):283–9. Apr.

Article  PubMed  Google Scholar 

Rosti G, Secondino S, Necchi A, Fornarini G, Pedrazzoli P. Primary mediastinal germ cell tumors. Semin Oncol. 2019;46(2):107–11. Apr.

Article  PubMed  Google Scholar 

Lobo J, Rodrigues Â, Henrique R, Christiansen A, Beyer J, Moch H, Bode PK. Morphological spectrum and molecular features of somatic malignant transformation in germ cell tumours. Histopathology. 2022;81(1):84–98. Jul.

Article  PubMed  Google Scholar 

Berney DM, Cree I, Rao V, Moch H, Srigley JR, Tsuzuki T, Amin MB, Comperat EM, Hartmann A, Menon S, Netto GJ, Rubin MA, Turajlic S, Raspollini MR, Tickoo SK. An introduction to the WHO 5th edition 2022 classification of testicular tumours. Histopathology. 2022;81(4):459–66. Oct.

Article  PubMed  PubMed Central  Google Scholar 

Wruck W, Bremmer F, Kotthoff M, Fichtner A, Skowron MA, Schönberger S, Calaminus G, Vokuhl C, Pfister D, Heidenreich A, Albers P, Adjaye J, Nettersheim D. The pioneer and differentiation factor FOXA2 is a key driver of yolk-sac tumour formation and a new biomarker for paediatric and adult yolk-sac tumours. J Cell Mol Med. 2021;25(3):1394–405. Feb.

Article  PubMed  PubMed Central  Google Scholar 

Taylor J, Donoghue MT, Ho C, et al. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. J Clin Invest. 2020;130:6668–76.

Article  PubMed  PubMed Central  Google Scholar 

Gillessen S, Sauvé N, Collette L, Daugaard G, de Wit R, Albany C, Tryakin A, Fizazi K, Stahl O, Gietema JA, De Giorgi U, Cafferty FH, Hansen AR, Tandstad T, Huddart RA, Necchi A, Sweeney CJ, Garcia-Del-Muro X, Heng DYC, Lorch A, Chovanec M, Winquist E, Grimison P, Feldman DR, Terbuch A, Hentrich M, Bokemeyer C, Negaard H, Fankhauser C, Shamash J, Vaughn DJ, Sternberg CN, Heidenreich A, Beyer J, Cell Cancer Classification Update Consortium IG. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. J Clin Oncol. 2021;10;39(14):1563–74. May.

Article  Google Scholar 

Beyer J, Collette L, Sauvé N, Daugaard G, Feldman DR, Tandstad T, Tryakin A, Stahl O, Gonzalez-Billalabeitia E, De Giorgi U, Culine S, de Wit R, Hansen AR, Bebek M, Terbuch A, Albany C, Hentrich M, Gietema JA, Negaard H, Huddart RA, Lorch A, Cafferty FH, Heng DYC, Sweeney CJ, Winquist E, Chovanec M, Fankhauser C, Stark D, Grimison P, Necchi A, Tran B, Heidenreich A, Shamash J, Sternberg CN, Vaughn DJ, Duran I, Bokemeyer C, Patrikidou A, Cathomas R, Assele S, Gillessen S, Cell Cancer Classification Update Consortium IG. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. J Clin Oncol. 2021;10;39(14):1553–62. May.

Article  Google Scholar 

Kesler KA, Rieger KM, Hammoud ZT, et al. A 25-year single institution experience with surgery for primary mediastinal nonseminomatous germ cell tumors. Ann Thorac Surg. 2008;85:371–8.

Article  PubMed  Google Scholar 

Feldman DR, Hu J, Dorff TB, et al. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. J Clin Oncol. 2016;34:2478–83.

Article  PubMed  PubMed Central  Google Scholar 

Schmoll HJ, Kollmannsberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 2003;21:4083–91.

Article  PubMed  Google Scholar 

Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, Einhorn L, Bokemeyer C. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol. 2002;13(7):1017–28. Jul.

Article  PubMed  Google Scholar 

Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol. 2014;15(13):1442–50. Dec.

Article  PubMed  Google Scholar 

Paffenholz P, Grein K, Heidegger I, Nestler T, Grabbert M, Salem J, Hellmich M, Pfister D, Heidenreich A. Predictors of thrombosis in testicular cancer during platinum-based chemotherapy. World J Urol. 2019;37(9):1907–16.

Article  PubMed  Google Scholar 

Kimakura M, Abe T, Nagahara A, Fujita K, Kiuchi H, Uemura M, Nonomura N. Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase. Anticancer Drugs. 2016;27(4):364–8. Apr.

Article  PubMed  PubMed Central  Google Scholar 

Heidenreich A, Haidl F, Paffenholz P, Pape C, Neumann U, Pfister D. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann Oncol. 2017 Feb 1;28(2):362–367

Albany C, Einhorn LH. Extragonadal germ cell tumors: clinical presentation and management. Curr Opin Oncol. 2013;25(3):261–5. May.

Article  PubMed  Google Scholar 

Joel A, Singh A, Hepzibah J, Devasia A, Kumar S, Gnanamuthu BR, Chandramohan A, George AJP, John NT, Yadav B, John AO, Georgy JT, John S, Chacko RT. End-of-Treatment FDG PET-CT (EOT-PET) in Patients with Post-Chemotherapy Masses for Seminoma: Can We Avoid Further Intervention? South Asian J Cancer. 2022;22;11(4):315–21. Aug.

Google Scholar 

Mishra S, Das Majumdar SK, Sable M, Parida DK. Primary malignant mediastinal germ cell tumors: A single institutional experience. South Asian J Cancer. 2020 Jan–Mar;9(1):27–29

Kier MG, Hansen MK, Lauritsen J, Mortensen MS, Bandak M, Agerbaek M, Holm NV, Dalton SO, Andersen KK, Johansen C, Daugaard G. Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer: A Danish Nationwide Cohort Study. JAMA Oncol. 2016;1;2(12):1624–7. Dec.

Article  Google Scholar 

Hartmann JT, Einhorn L, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Bokemeyer C. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol. 2001;15;19(6):1641–8. Mar.

Article  Google Scholar 

De Giorgi U, Demirer T, Wandt H, Taverna C, Siegert W, Bornhauser M, Kozak T, Papiani G, Ballardini M, Rosti G. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. Ann Oncol. 2005;16(1):146–51. Jan.

Article  PubMed  Google Scholar 

Nabil Adra, Rafat Abonour, Sandra K Althouse, Costantine Albany, Nasser H Hanna, Lawrence H Einhorn. High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience. J Clin Oncol2017 Apr 1;35(10):1096–1102.

Necchi A, Vullo LS, Giannatempo P, et al. Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. Ann Oncol. 2017;28:1346–51.

Article  PubMed  Google Scholar 

Adra N, Einhorn LH, Althouse SK, et al. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann Oncol. 2018;29:209–14.

Article  PubMed  Google Scholar 

Necchi A, Giannatempo P, Raggi D, et al. An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. Eur Urol. 2019;75:201–3.

Article  PubMed  Google Scholar 

Heidenreich A, Paffenholz P, Nestler T, Tolkach Y, Pfister D. Targeted Therapy in Patients with Metastatic Male Germ Cell Tumors. Urol Int. 2021;105(7–8:720–3.

Article  Google Scholar 

Necchi A, Bratslavsky G, Chung J, et al. Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart. Oncologist. 2019;24:e142–5.

Article  PubMed  PubMed Central  Google Scholar 

Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR. Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. J Clin Oncol. 2016;20;34(33):4000–7. Nov.

Article  Google Scholar 

Woldu SL, Matulay JT, Nirmish Singla TNC. Laura-Maria Krabbe Ryan C Hutchinson Arthur Sagalowsky , Yair Lotan. Aditya Bagrodia. Impact of hospital case volume on testicular cancer outcomes and practice patterns. Urol Oncol: Vitaly Margulis; 2018. Jan;36(1):14.e7–14.e15.

Google Scholar